NANOANTIBIOTICS INC

Inactive Instrument

Analyst Reco. Nanoantibiotics Inc Other OTC

Equities

US63009U1025

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 11	BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities	CI
Mar. 04	Top Midday Decliners	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts BioVie Price Target to $5 From $12, Maintains Outperform Rating	Nov. 30	MT
EF Hutton Adjusts Price Target for BioVie to $8 From $14, Maintains Buy Rating	22-09-28	MT
B. Riley Lowers BioVie's Price Target to $12 from $18 Reflecting More Sharpened Focus of Target Model, Keeps Buy Rating	22-07-28	MT
Cantor Fitzgerald Initiates BioVie at Overweight Rating With $7 Price Target	22-07-22	MT
EF Hutton Adjusts BioVie's Price Target to $14 from $9, Keeps Buy Rating	22-03-17	MT
Oppenheimer Starts BioVie at Outperform With $9 Price Target	22-03-15	MT
B. Riley Lowers BioVie's Price Target to $18 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
B. Riley Lowers BioVie's PT to $27 from $50 to Reflect Continued Expansion in Research, Development Spend, Stretched Out Commercialization Timelines; Keeps Buy Rating	21-11-30	MT
BIOVIE : B. Riley Raises BioVie's PT to $50 from $47 On Liver, Neurodegenerative, and Oncology Pipeline, Keeps Buy Rating	21-05-25	MT
DJ Industrial : Stocks Fall Ahead of Fed Rate Decision	21-04-28	MT
Midday Report: Wall Street Falls Ahead of Fed Rate Decision	21-04-28	MT
BIOVIE : B. Riley Starts BioVie at Buy With $47 Price Target	21-01-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer